Skip to content
Search

Latest Stories

Siddhant Chaturvedi and Malavika Mohanan team up for Yudhra

Siddhant Chaturvedi and Malavika Mohanan team up for Yudhra

By Murtuza Iqbal 

In 2021, many films have been announced, and now, here’s one more. Siddhant Chaturvedi and Malavika Mohanan will be seen together in a movie titled Yudhra which will be produced by Farhan Akhtar and Ritesh Sidhwani (Excel Entertainment) and directed by Ravi Udyawar.


Farhan took to Instagram to make an announcement about the film. He posted a teaser of the film and captioned it as, “Yudhra Announcement Karne sabka game over, aa raha hai #Yudhra. Releasing, summer 2022. @siddhantchaturvedi @malavikamohanan_ @raghavjuyal @raviudyawar @ritesh_sid @excelmovies @kassimjagmagia @shridhar_raghavan @ravibasrur @vishalrr @zeemusiccompany #AkshatGhildial #aafilmsindia.”

The makers have also shared a couple of posters of the film. Check them out here…

Yudhra looks like a romantic-action thriller, and both, Siddhant and Malavika are looking super stylish in the teaser.

Siddhant made his Bollywood debut with the 2019 release Gully Boy and impressed everyone with his performance in it. The actor has movies like Bunty Aur Babli 2, Shakun Batra’s next and Phone Bhoot lined-up.

Meanwhile, Malavika has been doing movies down South, but she is known for her performance in Majid Majidi’s Beyond the Clouds. The actress was last seen in Vijay starrer Master.

It will surely be interesting to watch the fresh pairing of Siddhant and Malavika on the big screen.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less